BME Stock Risk & Deep Value Analysis
Blackrock Health Sciences Trust
DVR Score
out of 10
What You Need to Know About BME Stock
We analyzed Blackrock Health Sciences Trust using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran BME through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
BME Risk Analysis & Red Flags
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Low
Execution
Medium
Regulatory
Medium
Upcoming Risk Events
- 📅
Underperformance of underlying health sciences portfolio
- 📅
Widening of the fund's discount to NAV
- 📅
General market downturn impacting risk assets
Unlock BME Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
BME serves as a professionally managed closed-end fund offering diversified exposure to the health sciences sector, primarily focused on total return and income generation through distributions. It is fundamentally unsuitable for investors seeking 10x growth potential within 3-5 years, as its structure as a fund precludes the direct operational leverage, market disruption, and exponential market share gains characteristic of such opportunities.
Is BME Stock Undervalued?
Unlock the full AI analysis for BME
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
BME Price Targets & Strategy
12-Month Target
$41.00
Bull Case
$44.00
Bear Case
$36.00
Valuation Basis
CEF valuation based on anticipated modest appreciation of underlying health sciences portfolio and potential for discount to NAV stabilization; 10x growth methodology is not applicable for a fund.
Entry Strategy
For income-seeking investors, consider dollar-cost averaging around current levels ($39-$40), especially if trading at a notable discount to NAV. Not recommended for 10x growth investors.
Exit Strategy
For income, hold long-term. For capital appreciation, consider profit-taking at $44.00; stop-loss at $36.00 (approaching recent forecast low).
Portfolio Allocation
0% for aggressive 10x growth portfolios; up to 1-3% for conservative income-focused portfolios seeking healthcare exposure.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is BME Financially Healthy?
Valuation
P/E Ratio
10.02
Forward P/E
10.02
EV/EBITDA
10.02
PEG Ratio
10.02
Price/Book
10.02
Price/Sales
10.02
Other
Dividend Yield
7.98%
Does BME Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable
Moat Sources
1 Identified
While BlackRock as an asset manager has a strong brand, BME as a specific fund does not possess a deep economic moat in terms of competitive advantages that would lead to 10x growth potential as an operating entity. Its durability relies on BlackRock's overall reputation and the health of the underlying sector.
Moat Erosion Risks
- •Increased competition from lower-cost ETFs for healthcare exposure
- •Underperformance relative to its benchmark or peer funds
- •Changes in investor preference for fund structures (e.g., CEFs vs. ETFs)
BME Competitive Moat Analysis
Sign up to see competitive advantages
BME Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, no specific data available in research.
Institutional Sentiment
Negative, institutional ownership is down 6.93% MRQ as of Nov 2025 filings.
Insider Activity (Form 4)
No Form 4 filings reported for purchases/sales by insiders (including CEO/CFO) in the last 90 days.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
N/A - As a CEF, BME reports NAV and distributions, not traditional quarterly earnings like operating companies.
Surprise Probability
N/A
Historical Earnings Pattern
N/A - As a CEF, stock price reaction is typically influenced by NAV changes, distribution announcements, and broader market sentiment for CEFs rather than traditional earnings beats/misses.
Key Metrics to Watch
Competitive Position
Top Competitor
Other Health Sciences CEFs/ETFs (e.g., HQL, THQ)
Market Share Trend
Not applicable for an investment fund.
Valuation vs Peers
Likely trades at varying discount/premium to NAV compared to similar CEFs/ETFs; specific comparison data not provided.
Competitive Advantages
- •BlackRock's reputable brand and asset management expertise
- •Diversified exposure to the health sciences sector
- •Professional portfolio management
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive BME Stock Higher?
Near-Term (0-6 months)
- •Monthly distribution announcements
- •Performance of underlying health sciences holdings
- •BlackRock's overall CEF market insights (e.g., Feb 2026 constructive view)
Medium-Term (6-18 months)
- •Sustained strong performance of the health sciences sector
- •Potential narrowing of the fund's discount to NAV
Long-Term (18+ months)
- •Continued growth and innovation in the broader healthcare industry
- •Consistent, long-term income generation for shareholders
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for BME?
- ✓
Significant shifts in the fund's premium/discount to NAV
- ✓
Major changes in distribution policy or amount
- ✓
Sustained underperformance of the underlying health sciences sector
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Blackrock Health Sciences Trust (BME)?
As of March 24, 2026, Blackrock Health Sciences Trust has a DVR Score of 0.7 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Blackrock Health Sciences Trust?
Blackrock Health Sciences Trust's market capitalization is approximately $535.2M..
What is the risk level for BME stock?
Our analysis rates Blackrock Health Sciences Trust's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of BME?
Blackrock Health Sciences Trust currently has a price-to-earnings (P/E) ratio of 10.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Does Blackrock Health Sciences Trust pay a dividend?
Yes, Blackrock Health Sciences Trust pays a dividend with a current yield of approximately 7.98%.
Is Blackrock Health Sciences Trust's revenue growing?
Blackrock Health Sciences Trust has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is BME stock profitable?
Blackrock Health Sciences Trust has a profit margin of 0.0%. The company is currently unprofitable.
How often is the BME DVR analysis updated?
Our AI-powered analysis of Blackrock Health Sciences Trust is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for BME (Blackrock Health Sciences Trust) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.